AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03227094 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Home-based OGTT (Beverage)
Description: In a random order Candy-OGTT (Jelly-Bean) or 75 g glucose beverage Glycemia every 15 minutes from CGMS collection; standardized condition (fasting + rest) Questionnaires
Study NCT03227094 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Home-based OGTT (Candy)
Description: In a random order Candy-OGTT (Jelly-Bean) or 75 g glucose beverage Glycemia every 15 minutes from CGMS collection; standardized condition (fasting + rest) Questionnaires
Study NCT03638362 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants consumed placebo beverage for 4 weeks.
Study NCT03638362 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tart cherry juice
Description: Participants consumed tart cherry juice (8 ounces; 240 mL) per day for four weeks.
Study NCT01415973 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 3 ounces of cooked, 85% lean ground beef
Description: Consumed once per subject.
Study NCT01415973 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 20 grams beef protein isolate
Description: Subjects would drink 200 ml water mixed with 20 grams of beef protein isolate one time.
Study NCT06332183 — intervention group
Intervention type: GENETIC
Intervention: Presence of polymorphisms
Description: Statistical analysis of GWAS data, Genome-wide methylation pattern analysis, Integration of GWAS data and methylation data (meQTL analysis), Pathway enrichment analysis
Study NCT02550093 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intervention 1
Description: Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of study drug prior to Thermal Evaluation System Testing on intervention 1 (Day 1).
Study NCT02550093 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Washout Period
Description: The wash-out period will be between intervention 1 and intervention 2. 13 days in length.
Study NCT02550093 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intervention 2
Description: Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of study drug prior to Thermal Evaluation System Testing on intervention 2 (Day 14).
Study NCT00415623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine 5mg/ day
Study NCT00415623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine 10mg/ day
Study NCT04312295 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACP-SCT program
Description: The ACP-SCT program was designed to improve nurses' knowledge and competence in discussing ACP with Chronic Kidney Disease patients.
Study NCT02838121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclasta
Description: Aclasta once annually for 2 years
Study NCT02838121 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No IV aclasta
Study NCT03006302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Epacadostat (100, 300, or 600 mg) is taken by mouth twice a day, every day.
Study NCT03006302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Pembrolizumab (200 mg) will be administered IV on day 1 of Cycles 1-6.
Study NCT02561481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulforaphane
Description: See under active arm description
Study NCT02561481 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See under placebo arm description
Study NCT02911298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole Benzoate gastro-resistant capsule with radio-labelled mucoadhesive formulation
Study NCT02911298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole Benzoate gastro-resistant capsule with radio-labelled non-mucoadhesive formulation
Study NCT03153891 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural Environment
Description: the natural environment will be delivered via Samsung VR gear goggles with Samsung smartphone.
Study NCT03153891 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Built Environment
Description: the built environment will be delivered via Samsung VR gear goggles with Samsung smartphone.
Study NCT04239261 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SBI
Description: Serum-derived Bovine immunoglobulin/protein isolate 10.0 g once daily
Study NCT04239261 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Hydrolyzed gelatin 10.0 g once daily
Study NCT03640507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine-alcohol
Description: Intervention is a 30-second vaginal preparation or topical wash with three chlorhexidine-alcohol 0.5% solution-soaked sponge sticks.
Study NCT03640507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidine-iodine
Description: Intervention is a 30-second vaginal preparation or topical wash with three povidine-iodine 10% solution-soaked sponge sticks.
Study NCT03640507 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile saline
Description: Intervention is a 30-second vaginal preparation or topical wash with three sterile saline-soaked sponge sticks.
Study NCT01545869 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fractional carbon dioxide laser
Description: SmartXide fractional carbon dioxide laser (DEKA, Florence, Italy). Parameters adjusted for: Power 20 watts, spacing 200 µsec, dwell time 300 µm, stacks 1.
Study NCT00708591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Oral Rapamycin once weekly at assigned dose in 4 week cycles. Dosing can continue until disease progression or severe side effects are seen.
Study NCT00708591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Twice daily (200mg each time) at the start of the second week of therapy for 4 consecutive days. Dosing continues every week after the second week of therapy.
Study NCT01648244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Decision Support
Description: The CADS software makes a recommendation about what medication changes are appropriate with potential alternates. CADS providers will either accept or reject the recommendation by the software.Providers with their patients are block randomized into CADS or Usual Care for 1 year. Patients associated with a CADS provider will upload their blood glucose data weekly and perform a 7-point glucose profile once per month. They will report major hypoglycemic events and hospitalizations at the time of their quarterly visit. Those getting usual care will be seen quarterly and will do self-monitoring of blood glucose and have A1c tests as determined by the provider but no less than twice a year.
Study NCT04432649 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4SCAR-276
Description: The 4SCAR-276 T cells can recognize and kill tumor cells through the recognition of CD276 .This study will evaluate the side effects and effective doses of 4SCAR-276 T cells in treating refractory and recurrent solid tumors
Study NCT01608737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PegIFN/RBV
Description: PegIFN/RBV for 48 weeks
Study NCT01608737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: BI 201335 once daily high dose for 12 weeks
Study NCT01608737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: BI 201335 once daily low dose for 24 weeks
Study NCT03034005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: 1600 ug inhaled daily for 6 weeks
Study NCT03614741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tinzaparin continuous infusion
Description: 4500 IU continuous infusion of Tinzaparin
Study NCT03614741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tinzaparin bolus
Description: 4500 IU bolus of Tinzaparin
Study NCT03066804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Description: Sacubitril/valsartan is available as 24 mg/26 mg, 49 mg/51 mg, 97 mg/103 mg, respectively in tablet form to be taken orally
Study NCT03066804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: Enalapril is available as 2.5 mg, 5 mg, and 10 mg tablet form to be taken orally
Study NCT03066804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Valsartan is available as 40 mg, 80 mg, 160 mg tablet form to be taken orally
Study NCT03066804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match sacubitril/valsartan
Description: Placebo to match LCZ696 50 mg, 100 mg, 200 mg tablet form to be taken orally
Study NCT03066804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match enalapril
Description: Placebo to match enalapril 2.5 mg, 5 mg, 10 mg tablet form to be taken orally
Study NCT03066804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match valsartan
Description: Placebo to match valsartan 40 mg, 80 mg, 160 mg tablet form to be taken orally
Study NCT03332654 — intervention group
Intervention type: OTHER
Intervention: Determine prevalence of stress urinary incontinence
Study NCT01888237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double dose of PPI
Description: Lansoprasole (30mg) 2 tab oral BID
Study NCT01888237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sequence of drug use
Description: lansoprazole 30 mg b.d. for 10 days amoxicillin 1000 mg b.d. (day 1 to day 5) metronidazole 400 mg b.d. (day 6-day 10) and clarithromycin 500 mg b.d. (day 6-day 10)
Study NCT02319993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIAN WANG BU XIN DAN
Description: assigned to TWBXD (n =48) and were instructed to take 6 gm 2 times per day of TWBXD for a period of 4 weeks.
Study NCT02319993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suan Tzao Ren Tang
Description: assigned to SZRT (n = 48) and were instructed to take 6 gm 2 times per day of SZRT for a period of 4 weeks.
Study NCT02319993 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1/10 TIAN WANG BU XIN DAN assigned to placebo (n =32) and were instructed to take 6 gm 2 times per day of placebo for a period of 4 weeks.
Study NCT03187106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin
Description: Other name(s): Keflex (cephalexin) Cephalexin at 500 mg per oral every 8 hours for a total of 6 doses
Study NCT03187106 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo representing standard of care
Study NCT02637167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: Rifaximin has negligible intestinal absorption after oral administration, giving it a good safety profile. Unlike systemically available antibiotics, this antimicrobial allows localized enteric targeting of bacteria and is associated with a minimal risk of systemic toxicity or side effects.
Study NCT02637167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saccharomyces boulardii
Description: The same advantage described above to Rifaximin applies to S. Boulardii, which might be therapeutically sufficient with the advantage of being less disruptive to the instestinal microbiota than broad-spectrum antibiotics.
Study NCT04687436 — intervention group
Intervention type: DEVICE
Intervention: mechanical cervical ripening
Description: mechanical cervical ripening with a foley catheter or double-balloon catheter or Cook cervical ripening balloon
Study NCT01880203 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: aspiration in thyroid node for Molecular Cytogenetic Analysis.
Study NCT01751204 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium tablet
Study NCT01751204 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium ion water (250mg)
Study NCT01751204 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium ion water (125mg)
Study NCT03006302 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRS-207
Description: CRS-207: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 (1 × 10\^9 CFU) will be administered IV on Day 2 of Cycles 3-6.
Study NCT03006302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Cyclophosphamide (200 mg/m\^2) will be administered IV on day 1 of Cycles 1 and 2.
Study NCT03006302 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVAX Pancreas Vaccine
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). GVAX will be administered on Day 2 of Cycles 1 and 2.
Study NCT02906761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 600 mg (2 tablets of 300 mg) twice daily for 6 months
Study NCT02906761 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (2 tablets) twice daily for 6 months
Study NCT03187106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Other name(s): Flagyl (metronidazole) Metronidazole at 500 mg per oral every 8 hours for a total of 6 doses
Study NCT00802139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venoferrum(iron sucrose)
Description: administer once weekly calculated quantity of Venoferrum® ampoules according to body weight and Hb level.
Study NCT00802139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bolgre (Iron acetyl-transferase)
Description: Twice daily administration with Bolgre® soln (one pouch per dosing which is equivalent to 40mg of iron) for 5 weeks
Study NCT02116296 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ToyBox-intervention
Study NCT02624908 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: canagliflozin
Description: Subjects randomized to active drug will receive canagliflozin 100 mg . If study drug well tolerated, dose will be increased to 300 mg canagliflozin at Visit 4.
Study NCT03936660 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intense Education Intervention
Description: Clinics provided with existing clinical care guidelines as well as a multifaceted educational intervention to support development of an integrated, multi-disciplinary care pathway for patients with T2DM and CVD.
Study NCT02871206 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluad
Study NCT02871206 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone
Study NCT02959229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactoferrin
Study NCT02959229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Lactoferrin)
Description: placebo in form of distilled water
Study NCT00968149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast sodium
Description: one montelukast chewable tablet daily at bed time for 2 weeks, 4 mg for patients aged 2-5 years and 5 mg for patients 6-14 years
Study NCT00968149 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: one placebo chewable tablet daily at bed time for 2 weeks
Study NCT02624908 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects randomized to placebo will receive 100 mg placebo pill . If study drug well tolerated, dose will be increased to 300 mg placebo pill at Visit 4.
Study NCT01521052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dTMS treatment (H1 Coil)
Description: All subjects will receive prefrontal deep rTMS of H1 Coil (42 trains of 2 seconds, 10 Hz, with 20 seconds inter-train intervals, up to 120% of motor threshold), for 4 weeks, 5 days a week, overall 20 sessions.
Study NCT04138316 — intervention group
Intervention type: DRUG
Intervention: Candesartan
Description: Treatment with Candesartan
Study NCT04687033 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: This instrument will be used to induce post-stroke motor recovery, two different monocephalic montages are typically used to restore excitability in the lesioned hemisphere and to down-regulate excitability of the non-lesioned hemisphere and rebalance Interhemispheric inhibition. each participant will undergo a 20-minute period of tDCS, applied at 2 mA through a pair of saline-soaked surface sponge electrodes (35 cm2).
Study NCT04687033 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: This instrument will be used to induce post-stroke motor recovery, two different monocephalic montages are typically used to restore excitability in the lesioned hemisphere and to down-regulate excitability of the non-lesioned hemisphere and rebalance Interhemispheric inhibition. each participant will undergo a 20-minute period of tDCS, applied at 2 mA through a pair of saline-soaked surface sponge electrodes (35 cm2).
Study NCT02135679 — intervention group
Intervention type: RADIATION
Intervention: Radiotherapy
Study NCT03024008 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BonoFill-II
Description: Surgery will be performed under local or general anesthetics according to the Investigator's and anesthesiologist discretion.~A standard orthopedic approach will be made according to the fracture site.Then the transplantation of BonoFill-II into the fracture site and the fixation of the fracture by intramedullary nail or plate and screws or external fixator as required will be performed.~internal fixation (plate and screws and intramedullary nails) will not be routinely removed. External fixators will be removed upon achievement of satisfactory bone union.
Study NCT01696916 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 6-minute walking test
Description: submaximum exercise test
Study NCT03941665 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gelronate
Description: Gel for topical use
Study NCT03941665 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gelronate
Description: Gel for topical use
Study NCT03941665 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aloevera
Description: Gel for topical use
Study NCT03941665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aloevera
Description: Gel for topical use
Study NCT01723267 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3D follicles assessment
Description: 3D ultrasound evaluation in IVF treatment (vs 2D ultrasound)
Study NCT01723267 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2D follicles assessment
Description: 2D ultrasound in IVF treatment (vs 3D ultrasound)
Study NCT04685655 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic plasma exchange
Description: Treatment with therapeutic plasma exchange. Plasma from healthy donors is used.
Study NCT00164788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous bolus injection of esomeprazole
Description: 80mg followed by continuous intravenous infusion of 8mg per hour for 24 hours
Study NCT00164788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral esomeprazole
Description: 40mg every 12 hours for 24 hours
Study NCT01586962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFF flavor 316 282, Paracetamol, Pseudoephedrine
Description: Single dose syrup containing a warmingflavor IFF 316282 in a syrup containing Paracetamol and pseudoephedrine
Study NCT01685372 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone High Dose
Description: A single-dose of high-dose influenza vaccine will be administered to subjects randomized to this arm
Study NCT01685372 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone
Description: A single-dose of standard-dose influenza vaccine will be administered to subjects randomized to this arm
Study NCT00882362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-14597 (Aripiprazole)
Description: administered orally once daily, 3 to 15 mg daily, 52 weeks
Study NCT00729560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutamide
Description: 250 mg twice daily for 4 weeks
Study NCT00729560 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice daily for 4 weeks
Study NCT01495260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: N-acetylcysteine, 800-2400 mg daily for 2 months
Study NCT01495260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lipoic acid
Description: lipoic acid, 300-600 mg daily for 2 months
Study NCT01495260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin E
Description: vitamin E, 150-300 mg daily for 2 months